A DMR was also identified in the BCL9L gene—an activator of Wnt signaling associated with B cell malignancies that have been implicated in cancer development and epithelial-mesenchymal transition through a down-regulation of c-Myc, cyclin D1, CD44, and vascular growth factor in tumor cells [89]. The gene discussed is CD44; the disease is neoplasm.